Featured Guest: Stan Mehr — Editor of Biosimilars Review & Report, healthcare journalist, and market strategist with decades of expertise in biosimilars, pharma reform, and drug pricing dynamics. https://biosimilarsrr.com/about/
In this critical episode, we explore the evolving biosimilars landscape, pricing transparency, and the tangled web of pharmacy benefit managers (PBMs) with biosimilars expert Stan Mehr. From inflated rebates to private-label manipulation, Stan sheds light on how PBMs and policy changes under the Inflation Reduction Act are reshaping access to lower-cost drugs.
If you're an employer, payer, or pharma manufacturer navigating the biosimilar space, this episode is your roadmap to understanding where opportunity lives—and where it's quietly being suffocated.
Key Topics Covered:
Michael's LinkedIn
Randy's LinkedIn
Sponsored by:
Peek: A game-changing prescription shopping solution that allows its members to view all their prescription cost options across cash discount programs and their insurance in one easy-to-use platform. Peek is currently being offered to organizations to help both employees and plan sponsors save money on their prescription spend. https://peekmeds.com/.
Institute for Integrated Health (IIH): Health care benefits, insurance coverage regulations, and doing business in the healthcare industry can be complicated. At IIH, Dr. Randy Vogenberg and his team understand these unique challenges and provides strategic guidance customized to every client. To help overcome your unique challenges, IIH delivers education, planning and advisory on market trends, and U.S. health care market intelligence. The firm’s decades of proven success are due to strategic collaboration with associates from the business, clinical, and scientific communities. https://iih-online.com/.
